Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …
cells from exhausted status and revive immune response against cancer cells. Based on the …
Tertiary lymphoid structures in cancer
TN Schumacher, DS Thommen - Science, 2022 - science.org
BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
[HTML][HTML] Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer
The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive
clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial …
clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial …
The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
N Kirchhammer, MP Trefny, P Auf der Maur… - Science translational …, 2022 - science.org
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …
[HTML][HTML] Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
WH Fridman, M Meylan, G Pupier, A Calvez… - Immunity, 2023 - cell.com
The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …
A “closed‐loop” therapeutic strategy based on mutually reinforced ferroptosis and immunotherapy
Y Du, R Zhang, J Yang, S Liu, J Zhou… - Advanced Functional …, 2022 - Wiley Online Library
The immunosuppression and immune escape of current immunotherapy result in low
efficacy, and ferroptosis is greatly restricted by the low reactive oxygen species (ROS) …
efficacy, and ferroptosis is greatly restricted by the low reactive oxygen species (ROS) …
Localization, tissue biology and T cell state—implications for cancer immunotherapy
JM Schenkel, KE Pauken - Nature Reviews Immunology, 2023 - nature.com
Tissue localization is a critical determinant of T cell immunity. CD8+ T cells are contact-
dependent killers, which requires them to physically be within the tissue of interest to kill …
dependent killers, which requires them to physically be within the tissue of interest to kill …